Immunotoxins in the therapy of cancer: from bench to clinic

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Murine monoclonal antibodies (mAbs) are key components in targeted cancer therapies.
• Conjugating mAbs to potent toxins enhances their therapeutic efficacy.
• Advancements in chemical coupling techniques have enabled the development of novel antibody-drug conjugates (ADCs).

Purpose of the Study:

• To review the progress of bench-to-clinic translational research for toxin-coupled murine monoclonal antibodies.
• To discuss the development, characterization, and preclinical testing of these targeted agents.
• To examine the clinical trial data and outcomes for antibody-drug conjugates.

Main Methods:

• Literature review focusing on studies involving murine mAbs chemically linked to toxins, their subunits, or ribosome-inactivating proteins.
• Analysis of data from preclinical models and human clinical trials.
• Evaluation of the rationale and scientific progress in ADC development.

Main Results:

• Several toxin-coupled murine mAb therapies have successfully transitioned from laboratory research to clinical application.
• Detailed characterization and preclinical testing have been crucial for advancing these agents.
• Clinical trials have demonstrated the potential and challenges of these targeted therapies.

Conclusions:

• Toxin-coupled murine monoclonal antibodies represent a significant advancement in targeted cancer therapy.
• The progression from bench to clinic highlights the importance of rigorous development and testing.
• Further research and clinical trials are essential to optimize the use of these agents in oncology.